No Abrupt Stops: What Clinicians Need to Know About the New Benzodiazepine Tapering Guideline

The Problem

Benzodiazepines remain among the most prescribed psychotropic medications in the United States, but their discontinuation has long lacked a unified, evidence-based framework. Many clinicians hesitate to taper for fear of withdrawal complications, while patients risk harm from long-term use or abrupt cessation. The new Joint Clinical Practice Guideline on Benzodiazepine Tapering, developed by the American Society of Addiction Medicine (ASAM) and nine partner organizations, seeks to change that.

Why It Matters

Abrupt discontinuation can precipitate severe withdrawal, including seizures, autonomic instability, and suicidality. At the same time, indefinite prescribing exposes patients to falls, cognitive decline, and overdose, particularly in older adults or those co-prescribed opioids. The new guideline offers a balanced, patient-centered roadmap for safe tapering that recognizes dependence as a physiological, not moral, phenomenon.

Key Takeaways

1. Language signals strength:
   • “Clinicians should/should not” = Strong recommendation
   • “Clinicians can consider” = Conditional recommendation
2. Never stop abruptly:
   • Tapering pace: 5–10% every 2–4 weeks, max 25% per 2 weeks
3. Patient-centered flexibility:
   • Pause, slow, or maintain a lower dose when symptoms interfere.
4. Harm reduction and co-management:
   • Offer naloxone for all BZD–opioid co-prescriptions.
   • Treat comorbid SUDs concurrently; do not discontinue buprenorphine or methadone.
5. Longer timelines are normal:
   • Many patients require months to years to safely taper.
6. Behavioral interventions matter:
   • Offer CBT or CBT-I to address underlying anxiety, insomnia, or trauma.

Beyond the Mic

Implementing this guideline isn’t just a pharmacologic challenge, it’s a systems challenge. Health systems face workforce shortages and limited behavioral health access. Policymakers must fund integrated taper clinics, therapy coverage, and pharmacist collaboration.

At its core, the guideline is an invitation to slow medicine, to privilege safety, dialogue, and individualized care over speed and standardization.

Featured Resources

• Tapering Benzodiazepine Medications: A Guide for Patients 
• Joint Clinical Practice Guideline on Benzodiazepine Tapering SpringerLink
• AGS Beers Criteria (2023 update): guidance for older-adult prescribing
• U.S. Food and Drug Administration

→ Listen to the full episode on The Transformed Minds  FULL EPISODE

Stay ready. Stay aware. Stay grounded.